COVID-19 and IBD [COVID-19]

  • Research type

    Research Study

  • Full title

    COVID-19 and Inflammatory Bowel Disease (IBD)

  • IRAS ID

    284761

  • Contact name

    Andrew Poullis

  • Contact email

    apoullis@sgul.ac.uk

  • Sponsor organisation

    St. George's University Hospitals NHS Foundation Trust

  • Duration of Study in the UK

    0 years, 2 months, 7 days

  • Research summary

    As a newly emerging health problem the evidence base and understanding of non-respiratory symptomatology during COVID-19 infection is very poor. Although COVID-19 primarily targets the respiratory system there is increasing evidence that the gastrointestinal tract is involved as well (Wan Y et al Lancet Gastroenterology and Hepatology 2020 doi: 10.1016/S2468-1253(20)30118-7). Inflammatory bowel disease (IBD) patients often need immunosuppressive therapy and are considered at higher risk of COVID-19 infection, but it is unclear currently how they are impacted by COVID-19. At St. George’s Hospital in partnership with Crohn’s Colitis UK (CCUK) we are in a unique position to identify and recruit large patient numbers to address these issues.\n\nThis study will investigate and describe the impact that COVID-19 has on patients with IBD. The areas that will be investigated will include compliance with IBD medication, the impact of COVID-19 on IBD, both direct and indirect, and knowledge about self-isolation and shielding.\n\nThe population to be studied will be all adults self-identified as having IBD who select to fill in on-line questionnaire hosted on the Crohn’s Colitis UK (CCUK) website or have been sent the link by CCUK. This will therefore be a convenience sampling study. CCUK has over 40,000 members, and there is no limit to study sample size.\n\nThe participants will complete a one-off secure online survey, containing quantitative information on their disease and the impact of COVID-19 on their IBD. No clinical interventions will take place during this study, and participants will not be exposed to any additional harm or benefit as a result of their participation.\n

  • REC name

    London - Bloomsbury Research Ethics Committee

  • REC reference

    20/PR/0057

  • Date of REC Opinion

    19 Jun 2020

  • REC opinion

    Further Information Favourable Opinion